AMGN Logo

Amgen Inc. (AMGN) 

NASDAQ
Market Cap
$172.93B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
431 of 776
Rank in Industry
9 of 10

Largest Insider Buys in Sector

AMGN Stock Price History Chart

AMGN Stock Performance

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment …

Insider Activity of Amgen Inc.

Over the last 12 months, insiders at Amgen Inc. have bought $0 and sold $3.96M worth of Amgen Inc. stock.

On average, over the past 5 years, insiders at Amgen Inc. have bought $0 and sold $7.55M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 6,020 shares for transaction amount of $1M was made by Hassan Fred (director) on 2015‑08‑19.

List of Insider Buy and Sell Transactions, Amgen Inc.

2024-05-03SaleSVP & CCO
2,117
0.0004%
$313.09$662,802+2.85%
2023-12-04SaleSVP & CCO
2,096
0.0004%
$273.03$572,276+12.19%
2023-11-08SaleEVP, Gen. Counsel & Secy.
10,000
0.0019%
$272.81$2.73M+10.97%
2023-08-10SaleEVP, Global Commercial Ops
9,558
0.0018%
$262.43$2.51M+5.68%
2022-11-09SaleSVP, Business Development
387
<0.0001%
$292.90$113,352-11.93%
2022-11-08SaleSVP & CCO
545
0.0001%
$293.54$159,977-12.76%
2022-08-22Sale
200
<0.0001%
$249.96$49,992-1.11%
2022-08-18Sale
6,600
0.0012%
$249.00$1.64M-2.22%
2022-05-23Sale
1,200
0.0002%
$250.00$300,000-0.65%
2022-05-10SaleEVP, Gen. Counsel & Secy.
27,000
0.0051%
$241.81$6.53M+3.63%
2021-05-12Saledirector
2,000
0.0002%
$161.12$322,230-6.81%
2021-05-11SaleSVP & CCO
5,000
0.0007%
$207.55$1.04M-7.35%
2021-05-07Saledirector
500
<0.0001%
$251.78$125,890-8.09%
2021-04-14Saledirector
2,000
0.0002%
$160.81$321,620-6.30%
2021-03-10Saledirector
2,000
0.0002%
$151.59$303,170+1.39%
2021-02-10Saledirector
2,000
0.0002%
$155.02$310,040-1.80%
2021-02-08Saledirector
500
<0.0001%
$119.00$59,498-1.43%
2021-02-04SaleEVP, Gen. Counsel & Secy.
22,220
0.0038%
$236.51$5.26M-1.28%
2021-01-13Saledirector
2,000
0.0002%
$118.00$235,990-0.60%
2020-11-09Saledirector
500
<0.0001%
$121.20$60,600+1.39%

Insider Historical Profitability

3.98%
Bradway Robert AChairman, CEO and President
383102
0.0713%
$321.7212+39.22%
MORROW GEORGE JExe VP, Global Commercial Ops
93719
0.0174%
$321.7214<0.0001%
CHOATE JERRY Ddirector
48575
0.009%
$321.7212<0.0001%
GLUCK FREDERICK Wdirector
15748
0.0029%
$321.7213<0.0001%
de Carbonnel Francoisdirector
15528
0.0029%
$321.7224+16.13%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$14.81B9.7152.09M+6.21%+$865.94M0.27
BlackRock$13.64B8.9447.97M+0.33%+$45.12M0.3
State Street$8.28B5.4329.13M-1.13%-$94.3M0.34
PRIMECAP Management Co$4.15B2.7214.6M+0.07%+$2.98M3.05
Morgan Stanley$3.97B2.6113.97M-3.2%-$131.38M0.29
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.